Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Okayama University research: Skipping a beat -- a novel method to study heart attacks


      News provided by

      Okayama University

      12 Nov, 2020, 09:39 GMT

      Share this article

      Share this article


      OKAYAMA, Japan, Nov. 12, 2020 /PRNewswire/ -- In a video-based study recently published in the Journal of Visualized Experiments (JoVE), researchers at Okayama University use stem cells to create a model of ischemic heart disease that closely replicates cardiac cells under stress.

      Ischemic heart disease often leads to heart attacks and is the leading cause of death worldwide. The condition manifests when the heart muscle does not receive adequate oxygen and eventually starts giving way. Scientists rely on animal models such as rats and mice to study ischemic heart disease. However, there are pronounced differences between the rodent and human heart, creating the need for a more "humanized" model. Now, a research team led by Research Associate Professor TAKAHASHI Ken and Professor NARUSE Keiji at Okayama University has created such a model using human stem cells.

      Stem cells have the unique ability to grow into any kind of specialized cell if given the right cocktail of growth factors. The team leveraged this property of stem cells and transformed them into heart muscle cells, or cardiomyocytes. To do so, human induced pluripotent stem cells (hiPSCs), a subset of stem cells, were first grown in incubators. Steadily growing hiPSCs were then differentiated into cardiomyocytes using a mix of factors promoting cardiac cell growth and subsequently incubated for 30 days. After this period, the cells were observed under a microscope to find that almost half of them had started contracting spontaneously, a property native to cardiomyocytes. Additionally, chemical assays showed that the cells were positive for cellular markers typically found within cardiac cells.

      To then induce ischemic heart disease, the newly formed cardiomyocytes were grown in a medium deprived of glucose, their primary energy source. Next, nitrogen gas was gradually released into the incubators holding the cells for 24 hours, creating a hypoxic environment. When observed again, only a small number of viable cells remained which were accompanied by a conspicuous reduction in contractility. Ischemia was thus successfully simulated, closely replicating the cell death that develops in ischemic cardiac disease.

      This study reports a novel and clinically relevant technique for studying ischemic cardiac disease in the laboratory. The condition was induced in cardiomyocytes derived from human stem cells mimicking patterns of damage seen in the human heart. This platform can eliminate the need for conducting complex procedures in animals and circumvent animal sacrifice. Moreover, the applications of the model in heart disease research are endless. "[This] model of ischemic heart disease, based on iPS CMs of human origin, can provide a useful platform for drug screening and further research on ischemic heart disease", conclude the researchers.

      Related video

      A video showcasing the experiments conducted in this study accompanies the article. Research Associate Professor TAKAHASHI research team from Okayama University depict a play-by-play of their newly developed research protocol in this video. All steps, starting from maintenance of the hiPSCs, followed by differentiation into cardiomyocytes, and the subsequent induction of ischemia are portrayed. The team also provides insights into measuring contractility along with a glimpse into the successful simulation of ischemic heart disease within the cardiomyocytes. This video will be especially useful for researchers in the field looking to replicate this model of ischemic heart disease for drug screening, genetic screening, or other research purposes.

      The video can be accessed at: https://www.jove.com/t/61104/model-ischemic-heart-disease-video-based-comparison-cardiomyocyte

      Background

      Ischemic heart disease – Ischemic heart disease is a fatal condition that stems from an inadequate blood supply to the heart muscles. The most common cause of ischemic heart disease is a blockage of the arteries supplying the walls of the heart due to blood clots or plaques. The cardiomyocytes then start dying due to a lack of oxygen, with patients often suffering heart attacks. Ischemic heart disease is the leading cause of mortality worldwide, and accounts for 40% of heart disease–related deaths in Japan. Thus, reliable and reproducible clinical models to study this condition are instrumental in developing prophylactic and therapeutic strategies.

      Reference

      Yun Liu, Yin Liang, Mengxue Wang, Chen Wang, Heng Wei, Keiji Naruse, Ken Takahashi. Model of Ischemic Heart Disease and Video-Based Comparison of Cardiomyocyte Contraction Using hiPSC-Derived Cardiomyocytes. Journal of Visualized Experiments, (159), e61104, 2020.

      DOI : 10.3791/61104

      https://www.jove.com/t/61104/model-ischemic-heart-disease-video-based-comparison-cardiomyocyte

      Correspondence to
      Research Associate Professor TAKAHASHI Ken, Ph.D.
      Department of Cardiovascular Physiology, Graduate, School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Shikata-cho 2-5-1,
      Okayama city, Okayama 700-8558, Japan 
      e-mail : takah-k2(a)okayama-u.ac.jp 
      For inquiries, please contact us by replacing (a) with the @ mark. 
      https://www.okayama-u.ac.jp/user/med/phy2/index.htm
      https://ken-takahashi.net/  

      Further information
      Okayama University
      1-1-1 Tsushima-naka , Kita-ku , Okayama 700-8530, Japan
      Public Relations Division
      E-mail: www-adm(a) adm.okayama-u.ac.jp
      For inquiries, please contact us by replacing (a) with the @ mark.
      Website: http://www.okayama-u.ac.jp/index_e.html  

      Okayama Univ. e-Bulletin: http://www.okayama-u.ac.jp/user/kouhou/ebulletin/  
      Okayama University Medical Research Updates (OU-MRU)
      http://research.okayama-u.ac.jp/research_pickups/

      The whole volume : OU-MRU (1- )
      https://www.okayama-u.ac.jp/eng/research/ou-mru.html 
      Vol.1:Innovative non-invasive 'liquid biopsy' method to capture circulating tumor cells from blood samples for genetic testing
      https://www.okayama-u.ac.jp/eng/release/index_id210.html

      Vol.82:Making memories — the workings of a neuron revealed
      https://www.okayama-u.ac.jp/eng/research_highlights/index_id116.html

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.